STEMTECH CORPORATION ELEVATES NETWORK MARKETING HALL OF FAMER IZZY MATOS TO FOUNDING INDEPENDENT BUSINESS PARTNER
Stemtech Corporation (OTCQB:STEK) announced the appointment of Izzy Matos as Founding Independent Business Partner. Matos, a key figure since the company's inception in 2005, previously developed the compensation plan and built a personal network of over 70,000 individuals. A graduate of the Network Marketing Hall of Fame, he aims to leverage this new role to enhance Stemtech's growth. The company, known for its patented stem cell nutrition products, has a strong history of recognition, having appeared on the Inc. 5000 Fastest-Growing Companies list multiple times.
- Appointment of Izzy Matos as Founding IBP could strengthen leadership and growth.
- Matos's vast experience in network marketing may enhance Stemtech's market presence.
- None.
MIRAMAR, FL, July 15, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (“Stemtech”) (OTCQB:STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that the Company appointed Network Marketing Hall of Famer Izzy Matos to Founding Independent Business Partner.
“Izzy started Stemtech by putting together the original compensation plan even before the company was officially founded in 2005,” said Charles S. Arnold, Chairman and CEO of Stemtech. “He was responsible for developing a personal organization of over 70,000 of the over 200,000 of our IBP’s and customers. In addition, Izzy traveled the globe at the request of Stemtech, opening our Markets and training countless distributors across the world: Out of over 55 million world-wide network marketers, Izzy is one of the 150 inducted into the Network Marketing Hall of Fame. He was also listed among the highest income earners in network marketing. He is
“Of all the accolades and accomplishments in my career, none has impacted me as much as being elevated to Founding IBP status,” said Izzy Matos. “Having been here from the company’s inception has afforded me opportunities to meet and help countless people around the globe achieve so many dreams. Now, in this new role, I can take those efforts to an even higher level. I am humbled, and grateful to our Board of Directors and Executive Team for their faith and confidence.”
“I have had the privilege of knowing and working with Izzy over the past sixteen years and know that he is a true leader in the network marketing industry and will help Stemtech rise to even greater heights in his new role as Founding IBP,” said John W. Meyer, President and COO of Stemtech.
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem®, OraStem® (Oral Health Care), and D-Fuze™ (EMF Blocker). Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on May 16th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
For Further Information, Contact:
Investor Relations: 954-715-6000, ir@stemtech.com
FAQ
Who is Izzy Matos in relation to Stemtech Corporation?
What is the significance of Matos's appointment for Stemtech?
What does Stemtech Corporation specialize in?
What stock symbol does Stemtech Corporation operate under?
